BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05384249 (izokibep in uveitis): BVCT ex-ante prediction vs. reported outcome

On 7 Dec 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 10 Dec 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05384249
Drug Name
izokibep
Drug MoA
IL-17A Inhibitor
Drug Modality
small protein scaffold-based biologic
Drug Class
Best-In-Class
Therapeutic Area
Eye Diseases
Indication
uveitis
Human Patients
96
Sponsor
ACELYRIN
Phase
Phase 2

Prediction of , index 1187

Prospective Prediction
Prediction Index
1187
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit in time to treatment failure and BCVA inferior to adalimumab + corticosteroids)
Technical Prediction
partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in time to treatment failure and BCVA compared with corticosteroids alone)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
3 days in advance
Readout Data Interpretation
izokibep failed to achieve statistical significance in the primary efficacy endpoint of time to treatment failure and secondary efficacy endpoint BCVA
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis
Phase
Phase 2
Status
Terminated
Enrollment
96
Lead sponsor
ACELYRIN Inc.
Conditions
Uveitis
Interventions
DRUG: Izokibep; DRUG: Placebo
Design
Randomized · Parallel · Double
Primary purpose
Treatment
Start
2022-08-23
Primary completion
2025-02-07
Completion
2025-02-07
Primary outcomes
  • Time to treatment failure defined as reaching treatment failure by meeting ≥ 1 of the 4 criteria specified in the protocol in at least 1 eye. (Up to Week 52)

NCT05384249 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials